• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射柠檬酸盐后铝代谢的个体间变异性。

Inter-subject variability in the metabolism of aluminium following intravenous injection as citrate.

作者信息

Talbot R J, Newton D, Priest N D, Austin J G, Day J P

机构信息

AEA Technology, Didcot, Oxon, UK.

出版信息

Hum Exp Toxicol. 1995 Jul;14(7):595-9. doi: 10.1177/096032719501400707.

DOI:10.1177/096032719501400707
PMID:7576820
Abstract
  1. Six healthy male volunteers received intravenous injections of 26Al as citrate. Accelerator mass spectrometry and gamma-ray spectrometry were used to determine levels of the tracer in blood and excreta at times up to 5-6 d. 2. There was a rapid clearance from blood (mean 2% of injection remaining after 1 d) and major loss in urine (59% up to 1 d), but 27 +/- 7 (s.d.)% was retained in the body at 5 d. Faecal excretion was negligible (1% up to 5 d). 3. The mean results accord with the early metabolic pattern in the single subject of a previous, more extensive study, who had retained 4% of the injection after 3 y. Together, the two studies point to the likelihood of large inter-subject differences in the long-term accumulation of dietary aluminium by populations receiving a given level of daily intake.
摘要
  1. 六名健康男性志愿者接受了柠檬酸形式的26Al静脉注射。使用加速器质谱法和伽马射线能谱法测定长达5 - 6天内血液和排泄物中示踪剂的水平。2. 血液清除迅速(1天后平均剩余注射量的2%),主要通过尿液排出(1天内达59%),但5天时27±7(标准差)%保留在体内。粪便排泄可忽略不计(5天内为1%)。3. 平均结果与先前一项更广泛研究中单个受试者的早期代谢模式相符,该受试者在3年后保留了注射量的4%。这两项研究共同表明,在摄入给定每日摄入量的人群中,长期累积膳食铝的个体间差异可能很大。

相似文献

1
Inter-subject variability in the metabolism of aluminium following intravenous injection as citrate.静脉注射柠檬酸盐后铝代谢的个体间变异性。
Hum Exp Toxicol. 1995 Jul;14(7):595-9. doi: 10.1177/096032719501400707.
2
The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers.26铝标记的柠檬酸铝和氢氧化铝在志愿者体内的生物利用度。
Biometals. 1996 Jul;9(3):221-8. doi: 10.1007/BF00817919.
3
Human metabolism of aluminium-26 and gallium-67 injected as citrates.以柠檬酸盐形式注射的铝-26和镓-67的人体代谢。
Hum Exp Toxicol. 1995 Mar;14(3):287-93. doi: 10.1177/096032719501400309.
4
Accelerator mass spectrometry: application to study of aluminum kinetics in the rat.加速器质谱分析法:在大鼠铝动力学研究中的应用
Am J Physiol. 1991 Mar;260(3 Pt 2):F466-9. doi: 10.1152/ajprenal.1991.260.3.F466.
5
Renal filtration and excretion of aluminium in the rat: dose-response relationships and effects of aluminium speciation.大鼠肾脏对铝的滤过与排泄:剂量反应关系及铝形态的影响
Hum Exp Toxicol. 1995 Jun;14(6):494-9. doi: 10.1177/096032719501400605.
6
Effect of citrate on plasma aluminium concentration and aluminium excretion in the rat.柠檬酸盐对大鼠血浆铝浓度及铝排泄的影响。
Clin Sci (Lond). 1992 Oct;83(4):431-5. doi: 10.1042/cs0830431.
7
Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide.柠檬酸钙显著增强了从氢氧化铝中铝的吸收。
Am J Kidney Dis. 1991 Jun;17(6):708-11. doi: 10.1016/s0272-6386(12)80356-8.
8
Effect of citrate infusion on urinary aluminium excretion in the rat.柠檬酸盐输注对大鼠尿铝排泄的影响。
Clin Sci (Lond). 1994 Feb;86(2):223-6. doi: 10.1042/cs0860223.
9
Aluminium deposition in liver and kidney following acute intravenous administration of aluminium chloride or citrate in conscious rats.清醒大鼠急性静脉注射氯化铝或柠檬酸盐后肝脏和肾脏中的铝沉积。
Hum Exp Toxicol. 1995 Oct;14(10):787-94. doi: 10.1177/096032719501401002.
10
Aluminum and lead absorption from dietary sources in women ingesting calcium citrate.
South Med J. 1994 Sep;87(9):894-8. doi: 10.1097/00007611-199409000-00006.

引用本文的文献

1
Extension and validation of a physiologically based toxicokinetic model for risk assessment of aluminium exposure in humans.用于人体铝暴露风险评估的基于生理学的毒代动力学模型的扩展与验证
Arch Toxicol. 2025 Jun;99(6):2379-2395. doi: 10.1007/s00204-025-04031-1. Epub 2025 Apr 19.
2
Progress towards Adjuvant Development: Focus on Antiviral Therapy.辅助药物研发进展:聚焦抗病毒治疗。
Int J Mol Sci. 2023 May 25;24(11):9225. doi: 10.3390/ijms24119225.
3
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.疫苗佐剂概述:当前证据与未来展望
Vaccines (Basel). 2022 May 22;10(5):819. doi: 10.3390/vaccines10050819.
4
Physiology-based toxicokinetic modelling of aluminium in rat and man.基于生理学的大鼠和人体内铝的毒代动力学模型。
Arch Toxicol. 2021 Sep;95(9):2977-3000. doi: 10.1007/s00204-021-03107-y. Epub 2021 Aug 14.
5
Aluminium release and fluid warming: provocational setting and devices at risk.铝释放和液体加热:激发状态和风险装置。
BMC Anesthesiol. 2021 May 27;21(1):163. doi: 10.1186/s12871-021-01378-7.
6
polysaccharide liposome as a novel strategy for stimulating an efficient immune response and their effects on dendritic cells.多糖脂质体作为一种刺激有效免疫反应的新策略及其对树突状细胞的影响。
Int J Nanomedicine. 2016 Dec 14;11:6795-6808. doi: 10.2147/IJN.S119108. eCollection 2016.
7
Aluminum bioavailability from basic sodium aluminum phosphate, an approved food additive emulsifying agent, incorporated in cheese.来自磷酸铝钠(一种已获批准的食品添加剂乳化剂)的铝生物利用度,该乳化剂添加于奶酪中。
Food Chem Toxicol. 2008 Jun;46(6):2261-6. doi: 10.1016/j.fct.2008.03.004. Epub 2008 Mar 10.
8
Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.铝、氧化铝和氢氧化铝的人体健康风险评估。
J Toxicol Environ Health B Crit Rev. 2007;10 Suppl 1(Suppl 1):1-269. doi: 10.1080/10937400701597766.
9
The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers.26铝标记的柠檬酸铝和氢氧化铝在志愿者体内的生物利用度。
Biometals. 1996 Jul;9(3):221-8. doi: 10.1007/BF00817919.